Christopher Badger

Jul 21, 2023 | onlinelibrary.wiley.com | Christian Cuba Samaniego |Jay Friedman |Xinping Yang |Christopher Badger

Abstract Background Treatment of patients with newly diagnosed HPV-associated oropharyngeal squamous cell carcinoma (OPSCC) with neoadjuvant chemotherapy (NAC) results in a high rate of 5-year recurrence free survival with few patients requiring adjuvant treatment. We hypothesized that NAC enhances primary tumor HPV-specific T cell responses. Methods HPV-specific responses in tumor infiltrating lymphocytes (TILs) before and after NAC were determined using autologous co-culture assays.